Results Participants and baseline characteristics A total of 53 patients were referred and assessed for eligibility between August/September 2021 and October 2023
However, if a patients insurance plan is willing to cover GLP-1s for weight loss, it may make more sense for them to go through a company that takes insurance
Bob Carter, deputy director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, told the New York Times this week, The magnitude of the improvement is of a scope we havent seen before with a drug
McGuire, a professor of medicine at the University of Texas Medical Center and the studys lead researcher
GLP-1 medications like semaglutide are not recommended for individuals with a history of: Medullary thyroid carcinoma (or a family history of it) Multiple endocrine neoplasia syndrome type 2 (MEN 2) Pancreatitis or gallbladder disease Severe gastrointestinal disorders FuturHealth clinicians screen all patients for these risk factors during the onboarding process
Like many chronic diseases, obesity has a wide range of causes and drivers, including those related to genetics, sociocultural factors, mental health, ultra-processed foods, economics, commercial determinants, and environmental factors